Healthcare Industry News: focused ultrasound
News Release - February 26, 2008
Misonix Announces Initial Sales into Ecuador
New Sales & Marketing Partner for This Latin American CountryFARMINGDALE, N.Y.--(HSMN NewsFeed)--Misonix, Inc. (Nasdaq: MSON), a developer of therapeutic ultrasonic medical device technology for the treatment of cancer and other acute or chronic health conditions, today announced that it has begun selling its SonaStar™ Ultrasonic Surgical Aspiration System into Ecuador in collaboration with B. Braun Medical, S.A. To date, three systems have been sold, shipped, and placed in hospitals. An order has been received for a fourth system, which will ship in the near future. Demographically, Ecuador is a country of approximately 14 million people with more than 300 hospitals.
B. Braun Medical S.A. is a subsidiary of B. Braun Melsungen AG, the German healthcare conglomerate with operations around the world. Aesculap, also owned by B. Braun, distributes the SonaStar™ exclusively for Misonix in the USA.
The SonaStar™ system allows physicians to perform the delicate, selective removal of tumors or other abnormal tissue while sparing vessels as much as possible. In addition, the system is capable of performing precise bone shaving (shaping) and is compatible with most electrocautery devices – controlling bleeding during certain surgical procedures.
About Misonix:
Misonix, Inc. (NASDAQ: MSON ) designs, develops, manufactures, and markets, therapeutic ultrasonic medical devices, and laboratory equipment. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Misonix has a minority equity position in Focus Surgery, Inc. which uses high intensity focused ultrasound technology to destroy deep-seated cancerous tissue without affecting surrounding healthy tissue. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix’s proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s Web site at www.misonix.com.
With the exception of historical information contained in this press release, content herein may contain “forward looking statements” that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company’s business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
Source: Misonix
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
